ÂÜÀòÂÒÂ×

Felix Scheuplein has a diverse work experience in the field of biology and drug discovery. Felix is currently serving as the Senior Director of Biology Drug Discovery at Blueprint Medicines since June 2016. Prior to this role, they worked as the Director of Biology Drug Discovery at the same company from November 2018 to June 2023. Before joining Blueprint Medicines, they held positions at NKT Therapeutics Inc., where they served as the Senior Laboratory Head of Preclinical Research from June 2012 to December 2015 and as a Senior Scientist from September 2009 to June 2012. Felix also worked as a Postdoctoral Fellow at The Jackson Laboratory from April 2006 to August 2009, where they focused on investigating the role of iNKT cells in T1D. Felix began their career with a PhD thesis at the Institute of Immunology, University of Hamburg, Germany, from April 2002 to March 2006 and a diploma thesis in genetics at the Department of Human Genetics, University Medical Center, Hamburg-Eppendorf, from March 2001 to December 2001.

Felix Scheuplein completed their education in the field of Immunology with a PhD from the University of Hamburg, from 2002 to 2006. Prior to that, they pursued a Dipl. Biol. degree in Genetics, Microbiology, and Informatics from the same university, between 1995 and 2002. Additionally, they have attended the JAX annual short course on mouse models in cancer research and a project management class at Massbio, although the exact duration and degrees obtained from these courses are not provided.